
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/475835/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Highly differential count of circulating and tumor infiltrating immune cells in patients with non-HCV/non-HBV hepatocellular carcinoma. Cancer Immunology, Immunotherapy, 2022, 71, 1103-1113.	4.2	7
2	The Role of Gut-Derived Lipopolysaccharides and the Intestinal Barrier in Fatty Liver Diseases. Journal of Gastrointestinal Surgery, 2022, 26, 671-683.	1.7	58
3	EMT-related genes are unlikely to be involved in extracapsular growth of lymph node metastases in gastric cancer. Pathology Research and Practice, 2022, 229, 153688.	2.3	1
4	A novel immune-related gene signature predicting survival in sarcoma patients. Molecular Therapy - Oncolytics, 2022, 24, 114-126.	4.4	8
5	Editorial: Cellular and Molecular Mechanisms of Immune Checkpoint Blockers in Anti-leukemia/Lymphoma Immune Therapy. Frontiers in Oncology, 2022, 12, 872300.	2.8	Ο
6	Perception of journal club seminars by medical doctoral students: results from five years of evaluation GMS Journal for Medical Education, 2022, 39, Doc4.	0.1	2
7	Experimental postoperative ileus: is Th2 immune response involved?. International Journal of Medical Sciences, 2021, 18, 3014-3025.	2.5	5
8	Cancer Vaccines: Antigen Selection Strategy. Vaccines, 2021, 9, 85.	4.4	30
9	Targeting the Intestinal Barrier to Prevent Gut-Derived Inflammation and Disease: A Role for Intestinal Alkaline Phosphatase. Visceral Medicine, 2021, 37, 383-393.	1.3	9
10	mRNA-Based Cancer Vaccines: A Therapeutic Strategy for the Treatment of Melanoma Patients. Vaccines, 2021, 9, 1060.	4.4	39
11	The predictive value of tumor infiltrating leukocytes in Hepatocellular Carcinoma: A systematic review and meta-analysis. European Journal of Surgical Oncology, 2021, 47, 2561-2570.	1.0	16
12	The interactions between major immune effector cells and Hepatocellular Carcinoma: A systematic review. International Immunopharmacology, 2021, 101, 108220.	3.8	6
13	Disulfide Dimerization of Neuronal Calcium Sensor-1: Implications for Zinc and Redox Signaling. International Journal of Molecular Sciences, 2021, 22, 12602.	4.1	8
14	The Advantages and Challenges of Anticancer Dendritic Cell Vaccines and NK Cells in Adoptive Cell Immunotherapy. Vaccines, 2021, 9, 1363.	4.4	20
15	The Importance of Cellular Metabolic Pathways in Pathogenesis and Selective Treatments of Hematological Malignancies. Frontiers in Oncology, 2021, 11, 767026.	2.8	26
16	Myeloid-Derived Suppressor Cells in Tumors: From Mechanisms to Antigen Specificity and Microenvironmental Regulation. Frontiers in Immunology, 2020, 11, 1371.	4.8	139
17	The Role of TIM-3 in Hepatocellular Carcinoma: A Promising Target for Immunotherapy?. Frontiers in Oncology, 2020, 10, 601661.	2.8	28
10	Mitashandria and Canaara 2020, 12, 2641		í

18 Mitochondria and Cancer. Cancers, 2020, 12, 2641.

3.7 6

#	Article	IF	CITATIONS
19	Angiogenesis-Related Gene Expression Signatures Predicting Prognosis in Gastric Cancer Patients. Cancers, 2020, 12, 3685.	3.7	25
20	A novel machine learning algorithm to predict disease free survival after resection of hepatocellular carcinoma. Annals of Translational Medicine, 2020, 8, 434-434.	1.7	21
21	Dendritic Cells in Anticancer Vaccination: Rationale for Ex Vivo Loading or In Vivo Targeting. Cancers, 2020, 12, 590.	3.7	56
22	Enhanced expression of CD39 and CD73 on T cells in the regulation of anti-tumor immune responses. Oncolmmunology, 2020, 9, 1744946.	4.6	37
23	The Role of Stellate Cells in Pancreatic Ductal Adenocarcinoma: Targeting Perspectives. Frontiers in Oncology, 2020, 10, 621937.	2.8	35
24	The role of interleukin-18 in pancreatitis and pancreatic cancer. Cytokine and Growth Factor Reviews, 2019, 50, 1-12.	7.2	37
25	Mechanisms of Metastasis in Colorectal Cancer and Metastatic Organotropism: Hematogenous versus Peritoneal Spread. Journal of Oncology, 2019, 2019, 1-13.	1.3	158
26	Interplay between ROS and Autophagy in Cancer and Aging: From Molecular Mechanisms to Novel Therapeutic Approaches. Oxidative Medicine and Cellular Longevity, 2019, 2019, 1-3.	4.0	27
27	Sestrins as a Therapeutic Bridge between ROS and Autophagy in Cancer. Cancers, 2019, 11, 1415.	3.7	40
28	Treatment with somatostatin analogs induces differentially expressed let-7c-5p and mir-3137 in small intestine neuroendocrine tumors. BMC Cancer, 2019, 19, 575.	2.6	17
29	Sestrins at the Interface of ROS Control and Autophagy Regulation in Health and Disease. Oxidative Medicine and Cellular Longevity, 2019, 2019, 1-11.	4.0	45
30	Monocytic HLA-DR Expression for Prediction of Anastomotic Leak after Colorectal Surgery. Journal of the American College of Surgeons, 2019, 229, 200-209.	0.5	7
31	Prognostic Impact of Tumor-Infiltrating Lymphocytes and Neutrophils on Survival of Patients with Upfront Resection of Pancreatic Cancer. Cancers, 2019, 11, 39.	3.7	84
32	Autoantibody against arrestin-1 as a potential biomarker of renal cell carcinoma. Biochimie, 2019, 157, 26-37.	2.6	11
33	Advances in the Development of Anticancer HSP-based Vaccines. Current Medicinal Chemistry, 2019, 26, 427-445.	2.4	7
34	In Vivo Immunological Effects of CD73 Deficiency. Cellular Physiology and Biochemistry, 2019, 52, 1193-1202.	1.6	2
35	Immunotherapy as an Option for Cancer Treatment. Archivum Immunologiae Et Therapiae Experimentalis, 2018, 66, 89-96.	2.3	19
36	Reactive oxygen species and colorectal cancer. Journal of Cellular Physiology, 2018, 233, 5119-5132.	4.1	105

#	Article	IF	CITATIONS
37	Editorial: Immune Checkpoint Molecules and Cancer Immunotherapy. Frontiers in Immunology, 2018, 9, 2878.	4.8	4
38	Immune Cell and Stromal Signature Associated With Progression-Free Survival of Patients With Resected Pancreatic Ductal Adenocarcinoma. Gastroenterology, 2018, 155, 1625-1639.e2.	1.3	152
39	Interferon-α Up-Regulates the Expression of PD-L1 Molecules on Immune Cells Through STAT3 and p38 Signaling. Frontiers in Immunology, 2018, 9, 2129.	4.8	83
40	Perivascular Tumor-Infiltrating Leukocyte Scoring for Prognosis of Resected Hepatocellular Carcinoma Patients. Cancers, 2018, 10, 389.	3.7	27
41	Development of novel biological resection criteria for safe and oncologically satisfying resection of hepatocellular carcinoma. Surgical Oncology, 2018, 27, 663-673.	1.6	7
42	Notch-Induced Myeloid Reprogramming in Spontaneous Pancreatic Ductal Adenocarcinoma by Dual Genetic Targeting. Cancer Research, 2018, 78, 4997-5010.	0.9	11
43	Association of differential miRNA expression with hepatic vs. peritoneal metastatic spread in colorectal cancer. BMC Cancer, 2018, 18, 201.	2.6	21
44	Metabolic Checkpoints: Novel Avenues for Immunotherapy of Cancer. Frontiers in Immunology, 2018, 9, 1816.	4.8	34
45	The Sabotaging Role of Myeloid Cells in Antiâ€Angiogenic Therapy: Coordination of Angiogenesis and Immune Suppression by Hypoxia. Journal of Cellular Physiology, 2017, 232, 2312-2322.	4.1	38
46	Temporary Intra-Operative Portocaval Shunts, Post-Operative Infections, and Mid-Term Survival after Cava-Sparing Liver Transplantation. Surgical Infections, 2017, 18, 803-809.	1.4	4
47	A marginal anticancer effect of regorafenib on pancreatic carcinoma cells in vitro, ex vivo, and in vivo. Naunyn-Schmiedeberg's Archives of Pharmacology, 2017, 390, 1125-1134.	3.0	8
48	MiRNAs are Unlikely to be Involved in Retinoid Receptor Gene Regulation in Pancreatic Cancer Cells. Cellular Physiology and Biochemistry, 2017, 44, 644-656.	1.6	10
49	Development of a reliable and accurate algorithm to quantify the tumor immune stroma (QTiS) across tumor types. Oncotarget, 2017, 8, 114935-114944.	1.8	21
50	The Analgesic Effect of the Mitochondria-Targeted Antioxidant SkQ1 in Pancreatic Inflammation. Oxidative Medicine and Cellular Longevity, 2016, 2016, 1-10.	4.0	7
51	Reactive Oxygen Species in Cancer Biology and Anticancer Therapy. Oxidative Medicine and Cellular Longevity, 2016, 2016, 1-2.	4.0	29
52	Mitochondria and Mitochondrial ROS in Cancer: Novel Targets for Anticancer Therapy. Journal of Cellular Physiology, 2016, 231, 2570-2581.	4.1	428
53	The novel mitochondriaâ€targeted antioxidant SkQ1 modulates angiogenesis and inflammatory micromilieu in a murine orthotopic model of pancreatic cancer. International Journal of Cancer, 2016, 139, 130-139.	5.1	18
54	The cancer-retina antigen recoverin as a potential biomarker for renal tumors. Tumor Biology, 2016, 37, 9899-9907.	1.8	24

#	Article	IF	CITATIONS
55	Interferon- \hat{I}^3 , interleukin-10 and interferon-inducible protein 10 (CXCL10) as serum biomarkers for the early allograft dysfunction after liver transplantation. Transplant Immunology, 2016, 34, 14-24.	1.2	12
56	Characterization of myeloid leukocytes and soluble mediators in pancreatic cancer: importance of myeloid-derived suppressor cells. Oncolmmunology, 2015, 4, e998519.	4.6	89
57	Anti-tumor properties of the cGMP/protein kinase G inhibitor DT3 in pancreatic adenocarcinoma. Naunyn-Schmiedeberg's Archives of Pharmacology, 2015, 388, 1121-1128.	3.0	2
58	In vitro immunomodulatory properties of gemcitabine alone and in combination with interferon-alpha. Immunology Letters, 2015, 168, 111-119.	2.5	12
59	Immunological in vivo effects of B7-H1 deficiency. Immunology Letters, 2014, 162, 273-286.	2.5	5
60	Influence of interferon- \hat{l}_{\pm} on the expression of the cancer stem cell markers in pancreatic carcinoma cells. Experimental Cell Research, 2014, 324, 146-156.	2.6	30
61	Reactive Oxygen Species in the Immune System. International Reviews of Immunology, 2013, 32, 249-270.	3.3	371